A Phase 3, Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled, Fixed-Dose Safety and Efficacy Study of SPD489 Compared With Placebo in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
Phase of Trial: Phase III
Latest Information Update: 04 Feb 2019
Price : $35 *
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Shire
- 25 Jan 2019 Status changed from recruiting to completed.
- 08 Sep 2017 Status changed from not yet recruiting to recruiting.
- 29 Aug 2017 Planned initiation date changed from 23 Aug 2017 to 6 Sep 2017.